case report aspiration glp-1 receptor agonist anesthesia 2023 Glucagon-Like Peptide-1 (GLP-1) Agonists: Risk of during PDF) Anesthesia in patients using

Purpose of Review The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity

It has been studied in human clinical trials and shown to support metabolic balance, healthy blood glucose regulation, inflammation management, and improved insulin function

The global obesity treatment market is expanding at unprecedented speed, with sales of weight-loss medications forecast to rise dramatically over the next decade.

The product is formulated to support healthy weight management

Learn what to expect from compounded GLP-1/GIP injections here.

Secondary outcomes were each of these events considered separately